| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/02/2008 | WO2008049920A2 Il-21 variants |
| 05/02/2008 | WO2008049881A2 Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
| 05/02/2008 | WO2008049866A1 New chelating compound |
| 05/02/2008 | WO2008049631A1 Sustained release formulations comprising very low molecular weight polymers |
| 05/02/2008 | WO2008049588A1 Lipid growth factor formulations |
| 05/02/2008 | WO2008049367A1 The use of plant seed protein extract and the pharmaceutical composition thereof |
| 05/02/2008 | WO2008049227A1 Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| 05/02/2008 | WO2008049197A1 Composition and method for reducing inflammation |
| 05/02/2008 | WO2008028888A3 Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting |
| 05/02/2008 | WO2008025830A3 Pharmaceutical and sunscreen compositions comprising caspase-14 |
| 05/02/2008 | WO2008025425B1 Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same |
| 05/02/2008 | WO2008017664A3 Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatement of hormone-dependent cancers and corresponding pharmaceutical kits |
| 05/02/2008 | WO2008015014A3 Cystatin from nematodes in the treatment of autoimmune or allergic diseases |
| 05/02/2008 | WO2008014410A3 Zimlig2 polynucleotides and polypeptides and methods of use |
| 05/02/2008 | WO2008014220A3 Vaccine immunotherapy |
| 05/02/2008 | WO2008010098A3 Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| 05/02/2008 | WO2008009977A3 Methods and compositions for modulating socs3 |
| 05/02/2008 | WO2008007322A3 Anti-hemorrhage medication pack |
| 05/02/2008 | WO2007147892A3 Use of inducer of promyelocytic leukemia protein (pml) for treating polyglutamine expansion neurodegenerative diseases |
| 05/02/2008 | WO2007112386A3 Gdf-9/bmp-15 modulators for the treatment of bone disorders |
| 05/02/2008 | WO2007098436A3 Platelet stabilization |
| 05/02/2008 | WO2007093975A3 Use of the pedf factor to induce cell regeneration |
| 05/02/2008 | WO2007052172A8 Methods for fusion polypeptide delivery into a cell |
| 05/02/2008 | WO2007028573A9 Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine |
| 05/02/2008 | WO2006026570A3 Use of stem cells to generate inner ear cells |
| 05/02/2008 | WO2005013885A3 Pharmaceutical compositions and methods for accelerating wound healing |
| 05/02/2008 | CA2703646A1 Peptide vaccine for influenza virus |
| 05/02/2008 | CA2693383A1 Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| 05/02/2008 | CA2667537A1 Metastin derivatives and use thereof |
| 05/02/2008 | CA2667536A1 Highly purified type a botulinum toxin preparation from infant botulism pathogen |
| 05/02/2008 | CA2667424A1 Sustained release formulations comprising very low molecular weight polymers |
| 05/02/2008 | CA2667332A1 Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| 05/02/2008 | CA2667280A1 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| 05/02/2008 | CA2667266A1 Hcv ns3 protease inhibitors |
| 05/02/2008 | CA2667260A1 Intracerebral oxidation inhibitor and use thereof |
| 05/02/2008 | CA2667165A1 Hcv ns3 protease inhibitors |
| 05/02/2008 | CA2667146A1 Hcv ns3 protease inhibitors |
| 05/02/2008 | CA2666991A1 Peptide-cytotoxic conjugates |
| 05/02/2008 | CA2666981A1 Soluble tnf receptors and their use in treatment of disease |
| 05/02/2008 | CA2666953A1 Spontaneous forming ellipsoidal phospholipid unilamellar vesicles |
| 05/02/2008 | CA2666629A1 Use of il-1 antagonists to treat gout and pseudogout |
| 05/02/2008 | CA2666609A1 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
| 05/02/2008 | CA2666562A1 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
| 05/02/2008 | CA2666426A1 Il-21 variants |
| 05/02/2008 | CA2632777A1 Organ preservation and/or perfusion |
| 05/01/2008 | US20080103457 Method and System for Treating Heart Failure |
| 05/01/2008 | US20080103299 Potency against gram-positive bacteria, methicillin-resistant Staphylococci aureus (MRSA), methicillin-resistant Staphylococci epidermitis (MRSE). |
| 05/01/2008 | US20080103294 Amino acid substitutions which increases protease resistance; linked to water soluble polymer (polyethylene glycol); improved half-life |
| 05/01/2008 | US20080103293 Amino acid substitutions which increases protease resistance; linked to water soluble polymer (polyethylene glycol); improved half-life |
| 05/01/2008 | US20080103292 Glycopeptide derivatives and pharmaceutical compositions containing the same |
| 05/01/2008 | US20080103290 Eluting from polystyrene divinyl benzene resin using acidified solution containing organic solvent; antibacterial |
| 05/01/2008 | US20080103109 Distributing polynucleotide in vivo using conditional vector that is transcriptionally active in normal cells and not in malfunctioning cells |
| 05/01/2008 | US20080103101 Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
| 05/01/2008 | US20080103100 Materials and methods for the treatment of celiac disease |
| 05/01/2008 | US20080103099 Apoptin-associating protein |
| 05/01/2008 | US20080103098 Recombinant Expression of Proteins in a Disulfide-Bridged, Two-Chain Form |
| 05/01/2008 | US20080103097 Glucagon-like peptides having one lipophilic substituent which is attached to the C-terminal amino acid; treatment of non-insulin dependent diabetes mellitus |
| 05/01/2008 | US20080103096 Muteins of Fibroblast Growth Factor 21 |
| 05/01/2008 | US20080103095 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 05/01/2008 | US20080103094 Targeted delivery of drugs for the treatment of viral infections |
| 05/01/2008 | US20080103093 Methods of treating cartilage defects |
| 05/01/2008 | US20080103092 Methods for Intradermal, Transdermal or Transmucosal Delivery of Biologically Active Substances |
| 05/01/2008 | US20080103091 Bi-functional peptides for multiple sclerosis treatment and diagnosis |
| 05/01/2008 | US20080103090 Polynucleotide; hybridization; recombinant vectors, host cells; diagnosis, prognosis; anticarcinogenic and antiproliferative agents; drug screening; genetic engineering |
| 05/01/2008 | US20080103089 Antacids based on use of proteins and their hydrolyzates, amino acids or of sodium salts of amino acids; and enzymatic treatment products such as plasteins and their alkaline derivatives for actual acid neutralizing capacity or for discomfort relief or both |
| 05/01/2008 | US20080103088 Combating disorders affecting mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells; polynucleotide obtained from Mollusca, Nematoda and Chordata; metabolic, cardiovascular, genetic, and nervous system disorders |
| 05/01/2008 | US20080103087 Azurin, pseudoazurin, plastocyanin, rusticyanin, Laz or auracyanin from Xylella, Pseudomonas, Alcaligene, Achromobacter, Bordetella, Methylomonas, Neisseria, or Vibrio; anticarcinogenic or antitumor agents; diabetic retinopathy, rheumatoid arthritis, psoriasis |
| 05/01/2008 | US20080102129 Aerosol delivery of insulin; absorption by lung tissue; determination of glucose concentration in blood; calibrating dosage of insulin |
| 05/01/2008 | US20080102128 formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s) |
| 05/01/2008 | US20080102125 For increasing plasma concentration of insulin-like growth factor-1; oximination with polyoxyethylene glycol |
| 05/01/2008 | US20080102124 Modified Human Growth Hormone |
| 05/01/2008 | US20080102115 Modified coagulation factor IX polypeptides and use thereof for treatment |
| 05/01/2008 | US20080102114 Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents |
| 05/01/2008 | US20080102109 Methods of enhancing solubility of agents |
| 05/01/2008 | US20080102101 Enhanced recovery following ocular surgery |
| 05/01/2008 | US20080102085 Vaccines for treatment of Aids; protein or polynucleotide is delivered via a bombardment approach |
| 05/01/2008 | US20080102083 Compositions and Methods for the Preparation of Human Growth Hormone Glycosylation Mutants |
| 05/01/2008 | US20080102077 Nucleic and Protein Sequences from the Hxhv Virus and Uses Thereof |
| 05/01/2008 | US20080102076 Immunostimulatory Compositions and Uses Thereof |
| 05/01/2008 | US20080102075 Enzymatic polypeptide which cleaves tumor necrosis factor receptor for use in treatment and prevention of arthritis and inflammatory disorders |
| 05/01/2008 | US20080102071 T cell inhibitory receptor compositions and uses thereof |
| 05/01/2008 | US20080102066 Ultrapure transferrin for pharmaceutical compositions |
| 05/01/2008 | US20080102064 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 05/01/2008 | US20080102060 Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 05/01/2008 | US20080102056 Marketing System for Improving Patient Compliance and Methods and Devices Relating to Same |
| 05/01/2008 | US20080102055 Method for detecting Alzheimer's disease |
| 05/01/2008 | US20080102054 Aorta gonad mesoderm composition for use in treatment of nervous system, blood, inflammatory, autoimmune, skin, respiratory and liver disorders |
| 05/01/2008 | US20080102032 Methods of Treating Diabetes Using Inhibitors of ARNT2 |
| 05/01/2008 | US20080099011 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume |
| 05/01/2008 | US20080099010 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 04/30/2008 | EP1916304A2 Antigenic polypeptides associated with multiple sclerosis and uses |
| 04/30/2008 | EP1916020A2 Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient |
| 04/30/2008 | EP1915999A1 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof. |
| 04/30/2008 | EP1915998A1 Prophylactic or therapeutic agent for corneal/conjunctival disease |
| 04/30/2008 | EP1915986A1 Lipid growth factor formulations |
| 04/30/2008 | EP1915621A2 Methods and compositions for diagnosis and treatment of viral and bacterial infections |
| 04/30/2008 | EP1915393A1 Selective vpac2 receptor peptide agonists |
| 04/30/2008 | EP1915392A2 Vegf-d and functional fragments thereof for bone repair |
| 04/30/2008 | EP1915391A1 Sra binding protein |
| 04/30/2008 | EP1915388A1 F11 receptor (f11r) antagonists as therapeutic agents |